

**Report from Finance & Business Development Committee following its meeting of 27<sup>th</sup> September 2017**

**Decisions / approvals made** (within delegated authority)

- .None

**Assurances provided to the Trust Board** (excluding Strategic Plan Actions / BAF)

See below

**Strategic Plan Actions** (Progress updates)

<p>Transforming How Cancer Care is Provided Across the Network</p>	<p>The Committee received an update on Building for the Future and progress with the build of the new hospital. The build is on plan and within budget allocation. The Committee also received assurance on the governance and performance monitoring arrangements that are being put in place between the Trust and PropCare.</p> <p>The Committee also received an update on the TCC programme. Overall the Programme has an Amber status at Month 5 . Two high risks with scores of 15 are (a) Potential for strategic drift relating to decision making with the future Clinical model and (b) Failure to redesign an affordable workforce. Both of these and actions to address appear on the Board Risk registrar.</p>
<p>Continuous Improvement and Innovation</p>	
<p>Financial sustainability</p>	<p>The Committee received the Month 5 Finance report. At Month 5 the Trust is reporting a surplus of £1.39m, a favourable variance of £6k against the planned position. Clinical activity is close to plan, the CIP programme is slightly ahead of plan.</p> <p>The Trust is on target to deliver its forecast year end surplus of £3.8m .</p> <p>The Trust's capital programme below plan - £6.3m against a plan of £17.9m at month 5 - due to the delayed start with the new build. The Trust's capital expenditure year end forecast has been revised to £20.4m.</p> <p>The committee requested that in future finance reports a schedule is included as a standing item to show cost and cash flow phasing for the new hospital build</p>

	<p>Radiotherapy activity continues to be below forecasted trajectory (12.9%). Further investigation and analysis is ongoing to understand the causes and options to address. It should be noted that this currently has no impact on the Trust's income due to the Block contract arrangement.</p> <p>NHSI has advised that there will be no formal Business Planning Round for 2018/19 and the current 2 year plans will stand. Trusts will have the opportunity to amend or refresh if they wish in quarter 4 of 2017/18. The Trust intends to take this window to update its Workforce plans and Activity and Capacity model to ensure alignment with the new Clinical Model. A joint report from the Director of Operations and the Finance Director will be considered by this committee in January and submitted to Board in February 2018.</p>
Generating Intelligence	
Delegated Actions from Board	
<p>Areas of non delivery:</p> <p>Radiotherapy activity ( see comments above)</p>	
<p>New / mitigated risks.</p> <p>.</p>	
<p>Key items for Board consideration</p> <ul style="list-style-type: none"> <li>• Refocussing future Board Development Sessions to focus on areas of strategic focus and interest.</li> </ul>	
<p>Recommendation</p> <p>Trust Board to note the report and detail any requests for further scrutiny or assurance.</p>	

**Report from Finance & Business Development Committee following its meeting of 25<sup>th</sup> October 2017**

**Decisions / approvals made** (within delegated authority)

The Committee received reports on

- the proposed business planning process for 2018/19. A 3year operational and financial plan will be considered in January for Board approval in February 2018.
- discussions of the Finance and Infrastructure sub -committees
- comparison of financial; performance based on 15 key financial indicators from 155 NHS FT accounts, Discussion focussed on the opportunity to obtain more detailed comparisons with specialist trusts
- the New Governance structure and proposed KPIs

**Assurances provided to the Trust Board** (excluding Strategic Plan Actions / BAF)

See below

**Trust Board Business Plan 2017/18 Actions** (Progress updates)

Transforming How Cancer Care is Provided Across the Network	
Continuous Improvement and Innovation	
Financial sustainability	The Trust is reporting a surplus of £1,756k against a plan of £1,726k. CIP savings of £951k have been achieved, £42K above plan. Financial risk rating is 1. The Private Clinic delivered a net profit for CCC of £580k at the end of Q2, with a full year forecast of £834k. Agency spend is below plan by £109k but by year end medical staffing is forecast to exceed the NHSI target of £511K by circa £150k.
Generating Intelligence	

**Delegated Actions from Board**

None

**Areas of non- delivery**

None

**New / mitigated risks**

None.

**Key items for Board consideration**

None

**Recommendation**

Trust Board to note the report and detail any requests for further scrutiny or assurance.